Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, Fälth M, Köllermann J, Walther R, Schlomm T, Sauter G, Bokemeyer C, Sültmann H, Schuppert A, Brümmendorf TH, Balabanov S. Ummanni R, et al. Among authors: barett c. PLoS One. 2011 Feb 11;6(2):e16833. doi: 10.1371/journal.pone.0016833. PLoS One. 2011. PMID: 21347291 Free PMC article.
Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro.
Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger HA, Brase JC, Kuner R, Schlomm T, Sauter G, Sültmann H, Korf U, Bokemeyer C, Walther R, Brümmendorf TH, Balabanov S. Ummanni R, et al. Among authors: barett c. J Proteome Res. 2012 Apr 6;11(4):2452-66. doi: 10.1021/pr201172n. Epub 2012 Mar 28. J Proteome Res. 2012. PMID: 22424448
Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.
Ummanni R, Jost E, Braig M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C, Sültmann H, Meyer-Schwesinger C, Brümmendorf TH, Balabanov S. Ummanni R, et al. Among authors: barett c. Mol Cancer. 2011 Oct 14;10:129. doi: 10.1186/1476-4598-10-129. Mol Cancer. 2011. PMID: 21999842 Free PMC article.
Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
Balabanov S, Wilhelm T, Venz S, Keller G, Scharf C, Pospisil H, Braig M, Barett C, Bokemeyer C, Walther R, Brümmendorf TH, Schuppert A. Balabanov S, et al. Among authors: barett c. PLoS One. 2013;8(1):e53668. doi: 10.1371/journal.pone.0053668. Epub 2013 Jan 9. PLoS One. 2013. PMID: 23326482 Free PMC article.
Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, Bosotti R, Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake TL, Brümmendorf TH. Balabanov S, et al. Among authors: barett c. PLoS One. 2011 Apr 26;6(4):e19164. doi: 10.1371/journal.pone.0019164. PLoS One. 2011. PMID: 21541334 Free PMC article.